Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1971 1
1972 1
1973 1
1974 1
1976 1
1981 1
1982 1
1983 3
1984 1
1985 4
1986 2
1987 1
1988 1
1989 1
1990 2
1991 3
1992 4
1993 5
1994 2
1995 4
1996 4
1997 5
1998 1
1999 6
2000 2
2001 5
2002 3
2003 3
2004 7
2005 9
2006 6
2007 8
2008 3
2009 8
2010 7
2011 13
2012 9
2013 17
2014 19
2015 32
2016 26
2017 28
2018 28
2019 28
2020 23
2021 38
2022 23
2023 13
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Thoracic Esophagus Adenocarcinoma"
Page 1
Pulmonary Large Cell Neuroendocrine Carcinoma.
Yang L, Fan Y, Lu H. Yang L, et al. Pathol Oncol Res. 2022 Oct 11;28:1610730. doi: 10.3389/pore.2022.1610730. eCollection 2022. Pathol Oncol Res. 2022. PMID: 36304941 Free PMC article. Review.
Esophageal Cancer: Tumor-Node-Metastasis Staging.
Betancourt-Cuellar SL, Benveniste MFK, Palacio DP, Hofstetter WL. Betancourt-Cuellar SL, et al. Radiol Clin North Am. 2021 Mar;59(2):219-229. doi: 10.1016/j.rcl.2020.11.008. Radiol Clin North Am. 2021. PMID: 33551083 Review.
Squamous cell carcinoma is the predominant histologic subtype worldwide whereas adenocarcinoma represents the majority of cases in North America, Australia, and Europe. ...
Squamous cell carcinoma is the predominant histologic subtype worldwide whereas adenocarcinoma represents the majority of cases in No …
Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides insights into clinical heterogeneity in reflux diagnosis.
Ong JS, An J, Han X, Law MH, Nandakumar P; 23andMe Research team; Esophageal cancer consortium; Schumacher J, Gockel I, Bohmer A, Jankowski J, Palles C, Olsen CM, Neale RE, Fitzgerald R, Thrift AP, Vaughan TL, Buas MF, Hinds DA, Gharahkhani P, Kendall BJ, MacGregor S. Ong JS, et al. Gut. 2022 Jun;71(6):1053-1061. doi: 10.1136/gutjnl-2020-323906. Epub 2021 Jun 29. Gut. 2022. PMID: 34187846 Free PMC article.
We hypothesised that the shared genetic architecture between GERD and these risk factors can be leveraged to (1) identify new GERD and Barrett's oesophagus (BE) risk loci and (2) explore potentially heterogeneous pathways leading to GERD and oesophageal complications. ...T …
We hypothesised that the shared genetic architecture between GERD and these risk factors can be leveraged to (1) identify new GERD and Barre …
Dissecting the genetic heterogeneity of gastric cancer.
Hess T, Maj C, Gehlen J, Borisov O, Haas SL, Gockel I, Vieth M, Piessen G, Alakus H, Vashist Y, Pereira C, Knapp M, Schüller V, Quaas A, Grabsch HI, Trautmann J, Malecka-Wojciesko E, Mokrowiecka A, Speller J, Mayr A, Schröder J, Hillmer AM, Heider D, Lordick F, Pérez-Aísa Á, Campo R, Espinel J, Geijo F, Thomson C, Bujanda L, Sopeña F, Lanas Á, Pellisé M, Pauligk C, Goetze TO, Zelck C, Reingruber J, Hassanin E, Elbe P, Alsabeah S, Lindblad M, Nilsson M, Kreuser N, Thieme R, Tavano F, Pastorino R, Arzani D, Persiani R, Jung JO, Nienhüser H, Ott K, Schumann RR, Kumpf O, Burock S, Arndt V, Jakubowska A, Ławniczak M, Moreno V, Martín V, Kogevinas M, Pollán M, Dąbrowska J, Salas A, Cussenot O, Boland-Auge A, Daian D, Deleuze JF, Salvi E, Teder-Laving M, Tomasello G, Ratti M, Senti C, De Re V, Steffan A, Hölscher AH, Messerle K, Bruns CJ, Sīviņš A, Bogdanova I, Skieceviciene J, Arstikyte J, Moehler M, Lang H, Grimminger PP, Kruschewski M, Vassos N, Schildberg C, Lingohr P, Ridwelski K, Lippert H, Fricker N, Krawitz P, Hoffmann P, Nöthen MM, Veits L, Izbicki JR, Mostowska A, Martinón-Torres F, Cusi D, Adolfsson R, Cancel-Tassin G, Höblinger A, Rodermann E, Ludwig M, Keller G, Metspalu A, … See abstract for full author list ➔ Hess T, et al. EBioMedicine. 2023 Jun;92:104616. doi: 10.1016/j.ebiom.2023.104616. Epub 2023 May 18. EBioMedicine. 2023. PMID: 37209533 Free PMC article.
Another aim was to examine whether cardia GC and oesophageal adenocarcinoma (OAC) and its precursor lesion Barrett's oesophagus (BO), which are all located at the gastro-oesophageal junction (GOJ), share polygenic risk architecture. ...All patients had a histopathol …
Another aim was to examine whether cardia GC and oesophageal adenocarcinoma (OAC) and its precursor lesion Barrett's oesophagus
Global and national trends in the age-specific sex ratio of esophageal cancer and gastric cancer by subtype.
Wang S, Zheng R, Arnold M, Abnet C, Zeng H, Zhang S, Chen R, Sun K, Li L, An L, Bray F, Wei W, He J. Wang S, et al. Int J Cancer. 2022 Nov 1;151(9):1447-1461. doi: 10.1002/ijc.34158. Epub 2022 Jun 22. Int J Cancer. 2022. PMID: 35678331 Free PMC article.
We aim to investigate the global age-specific sex differences in esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC), gastric cardia cancer (GCC) and gastric noncardia cancer (GNCC). ...
We aim to investigate the global age-specific sex differences in esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma
Pulmonary Combined Large Cell Neuroendocrine Carcinoma.
Li M, Yang L, Lu H. Li M, et al. Pathol Oncol Res. 2022 Nov 23;28:1610747. doi: 10.3389/pore.2022.1610747. eCollection 2022. Pathol Oncol Res. 2022. PMID: 36507119 Free PMC article. Review.
Currently, the treatment regimen of CLCNEC mainly refers to LCNEC that complete surgical resection is preferred in the early stage and according to previous researches, platinum-based small cell lung cancer (SCLC) standard treatment regimen showed promising results in postoperati …
Currently, the treatment regimen of CLCNEC mainly refers to LCNEC that complete surgical resection is preferred in the early stage and accor …
Management of Gastroesophageal Junction Tumors.
Okereke IC. Okereke IC. Surg Clin North Am. 2017 Apr;97(2):265-275. doi: 10.1016/j.suc.2016.11.004. Epub 2017 Feb 14. Surg Clin North Am. 2017. PMID: 28325186 Review.
PET-CT and endoscopic ultrasound are used to determine clinical stage. Depending on the location of the tumor in the esophagus and stomach, treatment can include chemotherapy with or without radiation, followed by surgery if there is no disease progression. ...
PET-CT and endoscopic ultrasound are used to determine clinical stage. Depending on the location of the tumor in the esophagus and st …
Esophageal Adenocarcinoma: Screening, Surveillance, and Management.
Mansour NM, Groth SS, Anandasabapathy S. Mansour NM, et al. Annu Rev Med. 2017 Jan 14;68:213-227. doi: 10.1146/annurev-med-050715-104218. Epub 2016 Aug 31. Annu Rev Med. 2017. PMID: 27618753 Review.
Esophageal adenocarcinoma (EAC) is a growing problem with a rapidly rising incidence. ...Acid suppression, nonsteroidal antiinflammatory drugs (NSAIDs), and statins may play a role in chemoprevention. Screening for Barrett's esophagus (BE), the only known precursor …
Esophageal adenocarcinoma (EAC) is a growing problem with a rapidly rising incidence. ...Acid suppression, nonsteroidal antiinflammat …
Advances in diagnosis and management of cancer of the esophagus.
Deboever N, Jones CM, Yamashita K, Ajani JA, Hofstetter WL. Deboever N, et al. BMJ. 2024 Jun 3;385:e074962. doi: 10.1136/bmj-2023-074962. BMJ. 2024. PMID: 38830686 Review.
Two distinct histological subtypes predominate, and should be considered biologically separate disease entities.1 These subtypes are esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC). Outcomes remain poor regardless of subtype, with most patient …
Two distinct histological subtypes predominate, and should be considered biologically separate disease entities.1 These subtypes are esophag …
Hepatoid Adenocarcinoma of the Lung.
Li M, Fan Y, Lu H. Li M, et al. Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211057983. doi: 10.1177/15330338211057983. Technol Cancer Res Treat. 2021. PMID: 34816785 Free PMC article.
Hepatoid adenocarcinoma of the lung (HAL) is an comparatively rare malignant tumor originating from the lung with shorter survival. ...The treatment strategy for HAL is similar to common lung adenocarcinoma. Complete surgical resection and adjuvant chemotherapy are …
Hepatoid adenocarcinoma of the lung (HAL) is an comparatively rare malignant tumor originating from the lung with shorter survival. . …
372 results